Oxford Gene Technology welcomes Sheffield Children’s NHS Foundation Trust to its CytoSure platform, and releases new cancer-focused array

Oxford Gene Technology (OGT), The Molecular Genetics Company, explores how Sheffield Children’s NHS Foundation Trust has seamlessly transferred to its CytoSure™ ISCA 8x60k platform, in a new case study entitled Evaluating and switching to CytoSure microarrays.

Read the full story -visit OGT’s website

It has also released its latest targeted array, the CytoSure Consortium Cancer +SNP array (4x180k), covering over 500 cancer genes and 130 cancer-associated genomic regions for hematological malignancies and solid tumours. The CCMC-approved  design  improves clinical research quality, using matched samples, which is a particular advantage in cancer research; and comes with CytoSure Interpret Software, which delivers reliable and user-friendly data analysis and provides rapid access to meaningful results.